Aligning T-cell biology with CAR design to improve lymphoma therapy
Official title: Aligning T-cell Biology with CAR Architecture to Enhance Lymphoma Therapy
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11431761 · Data updated 2026-11-12
A new NIH grant is exploring smarter CAR-T cell designs to make lymphoma treatment more durable and safer for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $413,339 |
| NIH project number | 1R01CA316454-01 |
| Project ID | NIH-11431761 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with B-cell non-Hodgkin lymphoma or related B-cell malignancies who may be candidates for CAR-T therapy in future trials.
✕Less likely to help
Patients who are not eligible for CAR-T therapy or who have disease types not targeted by this work may not benefit.
What this research studies
This project looks at how the cells used in CAR-T therapy and the way they are engineered affect how well people with B-cell lymphomas respond. By studying T-cell subsets, transcriptional programs, and cytokine environments, the team aims to create CARs that work with the patient’s own immune cells for longer-lasting responses. They plan to optimize manufacturing to preserve favorable T-cell states and potentially reduce severe side effects. The work combines laboratory studies with approaches that could move toward clinical testing in patients who need better lymphoma therapies.
Why it matters
Potential benefit: If successful, this work could lead to CAR-T therapies that produce longer-lasting remissions with fewer toxicities for people with B-cell lymphomas.
How similar studies have gone: Previous studies show that optimizing T-cell subsets and co-stimulatory signals can influence CAR-T efficacy and safety, supporting the potential for meaningful gains with this approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Melenhorst, Jan J — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Melenhorst, Jan J
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.